ArticleBritish journal of cancer2026
PD-1 inhibitor improves radiosensitivity by tumor vessel normalization.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Baseline dual-layer spectral CT-based habitat analysis for preoperative prediction of recurrence in pancreatic cancer after radical resection and its association with tumor-stroma ratio.Abdominal radiology (New York) · 2026Article
- Repurposing rosmarinic acid as an anti-colorectal cancer agent through bolstering T cell anti-tumor immunity by enhancing activation of MEK1-mediated TCR signaling.Cancer immunology, immunotherapy : CII · 2026Article
- Factors Affecting the Efficacy and Safety of First-Line Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer.Oncology research · 2026Article
- Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHost immunity status and hypoxia are the hallmarks of radiosensitivity. Induction of anti-PD-1 immunotherapy demonstrates promise in locally advanced tumor radiotherapy, but whether anti-PD-1 immunotherapy improves radiosensitivity is unclear.
methodsIn vivo experiments were performed in mouse models (4T1 and LLC) treated with anti-PD-1 antibodies or X-ray irradiation. Tumor tissues were subjected to bulk-RNA sequencing. The immune cell profile was characterised by flow cytometry. The hypoxia level was detected by immunofluorescence and Hypoxyprobe and measured using the hypoxia gene score. Vessel normalization was determined by the pericyte-endothelial cell ratio. Anti-CD4 and anti-CD8 monoclonal antibodies were used to deplete CD4
resultsInduction immunotherapy increased radiosensitivity and maximized anti-tumor response compared with concurrent administration of immunotherapy by mitigating hypoxia. Immune cell profile analysis showed that the number of CD4
conclusionsPD-1 inhibitors improve radiosensitivity through vasculature and immune reprogramming, and vessel normalization may be a biomarker for distinguishing patients who will benefit from radiotherapy after induction immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.